Progression-free survival can be predicted in epithelial ovarian cancer patients by in vitro chemosensitivity testing using the histoculture drug response assay - A prospective observational study in a single institution

Jung, P.S.; Kim, D.; Kim, J.; Kim, Y.; Nam, Joo‐Hyun; Lee, S.; Park, J.

doi:10.1016/j.ygyno.2013.04.454

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, platinum and paclitaxel antitumor agents showed the highest IRs of 10 drugs tested by the HDRA. This result was similar to that of a previous study in Korea (13), and supports the current combination of paclitaxel and carboplatin as the standard chemotherapy for ovarian cancer.…”

Section: Discussionsupporting

confidence: 91%

“…The HDRA is an in vitro test that measures how much a particular antitumor drug inhibits tumor tissue growth. A few reports have suggested the possibility of applying the HDRA to ovarian and colorectal cancer (13)(14)(15); however, this test had a limitation wherein it can help decide only one regimen at a time (16). The integrative tumor response assay was introduced and applied in ovarian cancer to overcome this challenge (17).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

Background/Aim: To retrospectively analyze the results of histoculture drug response assays (HDRAs) to determine whether the results could predict platinum sensitivity and prognosis in ovarian cancer. Patients and Methods: One hundred thirty-nine patients with ovarian cancer were reviewed. HDRAs were conducted for platinum and taxane agents. Platinum resistance and sensitivity occurred in 21 and 118 patients, respectively. To analyze the relationship between the inhibition rates (IRs) of tumor growth caused by the platinum agent and clinical outcomes, Student's t-test and linear regression analysis were used. Results: We found that the average IRs of the platinum and taxane agent were not statistically significant between the platinum-sensitive andresistant groups. There was no statistical significance for overall survival, progression-free survival, or platinum-free interval. Conclusion: The HDRA is not useful for predicting platinum sensitivity and survival outcomes.

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%